HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Regunera

FDA

Regulatory intelligence
FDAsafety guidance72% confidence

FDA AP — BUPRENORPHINE (SUPPL)

Source: FDA

Why This Matters

Why this matters: sets a safety guidance precedent in the same sub-indication (pain) as Veterans with Opioid Use Disorder.

Regulatory Analysis

Application ANDA204937. Sponsor: WATSON LABS TEVA. Submission status: AP. Submission type: SUPPL. Active ingredients: BUPRENORPHINE.

Supporting Context

Therapeutic area
Substance Use Disorder · Opioid Use Disorder
Sub-indication
Pain

Related signal: VA Study to Test Values-Based Intervention for Veterans in Buprenorphine Treatment

Source

View source document

Related Signal

Open signal — VA Study to Test Values-Based Intervention for Veterans in Buprenorphine Treatment
PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.